炒股就看金麒麟分析师研报，权威，专业，及时，全面，助您挖掘潜力主题机会！ 来源：中国基金报 【导读】指南针向全资子公司麦高证券增资1亿元，此前29亿元定增折戟 中国基金报记者 晨曦 麦高证券，增资新方案来了！ 12月4日晚间，指南针发布公告称，根据麦高证券经营发展需要，公司拟对麦高证券以自有资金增资1亿 元。 麦高证券为指南针的全资子公司。此次增资完成后，麦高证券的注册资本将由14亿元变更为15亿元。 对此，指南针表示，本次增资是为了更好地满足麦高证券业务发展的资金需要，有助于麦高证券业务的 稳定推进，符合公司长远规划和核心利益，为公司未来发展打下坚实基础。此次增资的资金来源为公司 自有资金，不会对公司当前财务状况和经营成果产生重大影响，不存在损害公司和全体股东利益的情 形。 同日，指南针还发布公告称，其董事会同意公司使用额度不超过3亿元的闲置自有资金购买债券。指南 针称，投资目的是提高公司资金使用效率、增加股东回报，合理利用闲置资金。 麦高证券由原网信证券更名而来，经历破产重整后，于2022年获指南针收购，成为其全资子公司。同 年，指南针抛出定增计划，募集资金在扣除费用后全部用于增资麦高证券。在2025年5 ...

Core Viewpoint - The company, Guiding Compass, is increasing its wholly-owned subsidiary, Maigao Securities, by 100 million yuan to support its business development needs after a failed 2.9 billion yuan fundraising attempt [2][5][6]. Group 1: Capital Increase - Guiding Compass announced a capital increase of 100 million yuan for Maigao Securities, raising its registered capital from 1.4 billion yuan to 1.5 billion yuan [5]. - The capital increase aims to better meet the funding needs of Maigao Securities and is aligned with the company's long-term planning and core interests [5][6]. Group 2: Previous Fundraising Attempt - The previous fundraising plan, which aimed to raise up to 2.9 billion yuan, was terminated after three years due to various internal and external factors [6]. - The decision to terminate the fundraising was made after careful analysis and consideration of the company's strategic goals [6]. Group 3: Financial Performance of Maigao Securities - Maigao Securities has begun to recover from previous years of losses, reporting a revenue of 324 million yuan and a net profit of 70.36 million yuan in the first half of 2025 [6]. - For the first three quarters of 2025, Maigao Securities achieved a net income from fees and commissions of 366 million yuan, a year-on-year increase of 171.07% [6]. - The net interest income for the same period was 70.84 million yuan, reflecting a growth of 54.46% year-on-year [6].

Group 1 - China Pacific Insurance has received approval from the financial regulatory authority for Wang Yuhua to serve as a director [1] - Shanghai Bank announced that the regulatory authority has approved Chen Lei's qualification as vice president [2] - Shanghai HuGong has decided to terminate the "Aerospace Equipment Manufacturing Base" fundraising project due to significant changes in project feasibility [3] Group 2 - Dongwang Times plans to reduce its stake by up to 1.20% through share sales [4] - Zhinancun intends to increase its capital by 100 million yuan in its wholly-owned subsidiary, Maigao Securities [5] - Jinxinnong reported a sales revenue of 115 million yuan from pig sales in November [6] Group 3 - Tiantan Biological has completed the Phase III clinical trial of its human prothrombin complex, showing good efficacy and safety for hemophilia B patients [7] - Beijete's subsidiary has signed a framework agreement for equity acquisition to gain control of Yunnan Wenye Nonferrous Metals [8] - Zhongsheng Pharmaceutical's RAY1225 injection has received approval for a new clinical trial indication for treating metabolic-associated fatty liver disease [9] Group 4 - Enhua Pharmaceutical's hydrochloride sulpiride tablets have passed the consistency evaluation for generic drugs [10] - Shenkong Co. plans to invest 60 million yuan in a semiconductor industry fund [11] - Lianhuan Pharmaceutical's subsidiary has received approval for its drug to pass the consistency evaluation for generic drugs [12] Group 5 - Dazhong Transportation has received approval to issue debt financing tools totaling 4.5 billion yuan [13] - Jintian Titanium Industry plans to invest 50 million yuan in an industry merger and acquisition fund [14] - Changchun Gas has committed over 1.7 billion yuan to gas facility upgrades [15] Group 6 - Laimei Pharmaceutical's innovative anti-cancer drug "Nano Carbon Iron" has received approval for clinical trials [16] - Longquan Co. has signed supply contracts worth approximately 50.76 million yuan for nuclear power components [17] - Igor plans to distribute a cash dividend of 1 yuan per 10 shares [18] Group 7 - Xingfa Group's subsidiary has signed a processing agreement for 80,000 tons of lithium iron phosphate [20] - Yunjigroup's director Wang Wanfeng has resigned for personal reasons [21] - Saiseng Pharmaceutical's application for the listing of a new drug has been accepted by the regulatory authority [22] Group 8 - Xinhua Medical has obtained registration certificates for two new medical devices [23] - Chaoying Electronics plans to invest 100 million USD in its Thai subsidiary for an AI circuit board expansion project [24] - Suzhou Planning's application to acquire 100% of Dongjin Aviation has been accepted by the Shenzhen Stock Exchange [25]

指南针12月4日公告，董事会审议通过向全资子公司麦高证券增资1亿元的议案。增资完成后，麦高证券 注册资本将增至15亿元。增资旨在满足麦高证券业务发展需求，资金来源为公司自有资金，不会对公司 财务状况产生重大影响。 ...

格隆汇12月4日丨指南针(300803.SZ)公布，第十四届董事会第十二次会议，审议通过《关于使用部分闲 置自有资金购买债券的议案》，同意公司使用额度不超过人民币3亿元的闲置自有资金购买债券（风险 等级在AA以上），有效期自本次董事会批准之日起12个月。在有效期及额度范围内可循环滚动使用。 ...

Group 1 - The core point of the article is that the company, Guiding Compass, announced a board meeting to discuss a capital increase for its wholly-owned subsidiary, Maigao Securities [1] - For the year 2024, the revenue composition of Guiding Compass is as follows: Internet financial services account for 79.22%, securities business for 20.76%, and other businesses for 0.02% [1] - As of the report date, the market capitalization of Guiding Compass is 74.1 billion yuan [1] Group 2 - The article also highlights developments in China's commercial aerospace sector, focusing on cost reduction and reuse strategies, indicating a competitive environment with multiple companies involved [1]

格隆汇12月4日丨指南针(300803.SZ)公布，根据麦高证券经营发展需要，公司拟对麦高证券以自有资金 增资1亿元。本次增资完成后，麦高证券的注册资本将由14亿元变更为15亿元，麦高证券仍为公司全资 子公司。 ...

指南针(300803.SZ)公告称，公司于2025年12月4日召开董事会，审议通过向全资子公司麦高证券增资1 亿元的议案。增资完成后，麦高证券注册资本将增至15亿元。增资旨在满足麦高证券业务发展需求，资 金来源为公司自有资金，不会对公司财务状况产生重大影响。 ...

证券代码：300803 证券简称：指南针 公告编号：2025-104 北京指南针科技发展股份有限公司 关于使用部分闲置自有资金购买债券的公告 3．投资方式：购买债券（风险等级在 AA 以上）。 4．投资期限：有效期自本次董事会批准之日起 12 个月。 5．资金来源：自有资金。 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假记载、误导 性陈述或重大遗漏。 北京指南针科技发展股份有限公司（以下简称"公司"）于 2025 年 12 月 4 日召开了第十四届董事会第十二次会议，审议通过《关于使用部分闲置自有资金 购买债券的议案》，同意公司使用额度不超过人民币 3 亿元的闲置自有资金购买 债券（风险等级在 AA 以上），有效期自本次董事会批准之日起 12 个月。在有 效期及额度范围内可循环滚动使用。 本次使用部分闲置自有资金购买债券不构成关联交易，不构成《上市公司重 大资产重组管理办法》规定的重大资产重组。现将相关情况公告如下： 一、 投资情况概述 1．投资目的：为了提高公司资金使用效率、增加股东回报，合理利用闲置 资金，在不影响公司正常经营的情况下，使用公司部分暂时闲置自有资金购买债 券。 2．投 ...

证券代码：300803 证券简称：指南针 公告编号：2025-103 北京指南针科技发展股份有限公司 关于向全资子公司麦高证券有限责任公司增资的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假记载、误 导性陈述或重大遗漏。 北京指南针科技发展股份有限公司（以下简称"公司"或"指南针"）于 2025 年 12 月 4 日召开第十四届董事会第十二次会议，审议通过了《关于向全资 子公司麦高证券有限责任公司增资的议案》，董事会同意公司向全资子公司麦高 证券有限责任公司（以下简称"麦高证券"）增资，并同意授权公司经营管理层 具体决定和办理上述增资相关事项。详情如下： 一、向麦高证券增资情况概述 注册资本：140,000 万元人民币 成立日期：1995 年 4 月 18 日 根据麦高证券经营发展需要，公司拟对麦高证券以自有资金增资 1 亿元（人 民币，下同）。本次增资完成后，麦高证券的注册资本将由 14 亿元变更为 15 亿 元，麦高证券仍为公司全资子公司。 根据相关法律法规及《公司章程》规定，本次向子公司增资事项在董事会审 批权限范围内，无需提交股东会审议。本次向子公司增资事项不构成关联交易， ...